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A B S T R A C TObjective: Cost-utility analysis is widely used in high-income coun-
tries to inform decisions on efﬁcient health care resource allocation.
Cost-utility analysis uses the quality-adjusted life-year as the out-
come measure of health. High-income countries have undertaken
health state valuation (HSV) studies to determine country-speciﬁc
utility weights to facilitate valuation of health-related quality of life.
Despite an evident need, however, the extent of HSVs in low- and
middle-income countries (LMICs) is unclear. Methods: The literature
was searched systematically by using four databases and additional
Web searches to identify HSV studies carried out in LMICs. The
Preferred Reporting System for Systematic Reviews and Meta-
Analysis (PRISMA) strategy was followed to ensure systematic selec-
tion of the articles. Results: The review identiﬁed 17 HSV studies from
LMICs. Twelve studies were undertaken in upper middle-income
countries, while lower middle- and low-income countries contributedsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.05.006
na@grifﬁth.edu.au.
ndence to: Sanjeewa Kularatna, Centre for Appl
lia.three and two studies, respectively. There were 7 generic HSV and 10
disease-speciﬁc HSV studies. The seven generic HSVs included ﬁve
EuroQol ﬁve-dimensional questionnaire, one six-dimensional health
state short form (derived from short-form 36 health survey), and one
Assessment of Quality of Life valuations. Time trade-off was the
predominant valuation method used across all studies. Conclusions:
This review found that health state valuations from LMICs are
uncommon and utility weights are generally unavailable for these
countries to carry out health economic evaluation. More HSV studies
need to be undertaken in LMICs to facilitate efﬁcient resource
allocation in their respective health systems.
Keywords: health state valuation, LMIC, preference, QALY, utility.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health economic evaluations and health technology assessments
are performed in many high-income countries to assist decisions
about the allocation of health resources. It is unclear, however,
whether any low- and middle-income countries (LMICs) have
adopted this approach [1]. There appear to be many barriers
against the adoption of health economic evaluations as formal
tools for decision making in LMICs.
Over the past decade, cost-utility analysis (CUA) has become
used extensively in high-income countries to prioritize health
care interventions and inform government subsidy decision-
making processes [2]. Many health advisory institutions in West-
ern Europe, Canada, and Australia recommend the use of health
economic evaluations to inform decisions, and use quality-
adjusted life-years (QALYs) [3–5] or disability-adjusted life-years
(DALYs) [6,7] as outcome measures. Most applications of DALYs
do not use country-speciﬁc valuations of health states. Apreference for the same health state (e.g., leg fracture/HIV
infection/blindness) could be quite different in different coun-
tries. Preferences can vary, inter alia, by cultural belief [8],
availability of health care, and support from social institutions.
Thus, the use of weights derived from preferences of people
living elsewhere and differences in methods of deriving utility
weights can have a signiﬁcant impact on the resulting CUA [9,10].
This review focuses on country-speciﬁc utility weights for QALYs
on the basis that DALYs differ signiﬁcantly from QALYs as the
outcome measure for economic evaluation [8]. The estimation of
QALYs requires weights (utility weights) to account for the
quality adjustment of survival for different states of health
(health states). Utility weights denote the strength of preference
or the desirability of a given speciﬁc health state. In estimating
utility weights, three questions need to be answered: what is to
be valued; how is it to be valued; and who is to value it [9]. A set of
health states described with the aid of a multiattribute utility
instrument (MAUI) is valued by using a preference elicitationociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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(SG) [11], or more recently discrete choice experiments (DCEs)
[12]. Usually, the general population of the country where the
weights are to be used should provide the valuation [10,13]. There
are, however, other dissenting arguments such as valuation by
patients [14]. Utility weights developed by using this approach
have been made available in high-income countries over the last
two decades [13,15–19]. Generic health state valuations (HSVs)
such as the EuroQol ﬁve-dimensional (EQ-5D) questionnaire and
six-dimensional health state short form (derived from short-form
36 health survey) (SF-6D) usually provide a national value set that
can be used in health care decision making. Because of a lack of
sensitivity of generic MAUIs in speciﬁc disease conditions [20],
cancer, for example, speciﬁc HSVs using disease-speciﬁc MAUI
should also be considered.
The World Bank classiﬁed countries according to their annual
per capita income in 2011 as low income (US $1,025 or less), lower
middle income (US $1,026–$4,035), upper middle income (US
$4,036–$12,476), and high income (4US $12,476) [21]. An LMIC is
deﬁned as a country with low-, lower middle- and upper middle-
income citizens [21]. In LMICs, the availability of utility weights is
of increased importance because these countries require efﬁcient
health care resource allocation because of scarce resources and
high disease burden [22]. The availability of utility weights could
facilitate CUA for efﬁcient health resource allocation in these
countries. Utility weights derived from the preferences of a
population of a given country have been reported to be different
from those derived from other countries [23,24]. Utility weights
differ signiﬁcantly even among high-income countries [23]. More-
over, widely different socioeconomic, cultural, and social con-
ditions between high-income countries and LMICs make it
imperative that country-speciﬁc utility weights be used in health
economic evaluations. For example, the quality of life (QOL)
associated with poliomyelitis in an LMIC has far greater con-
sequences, such as physical limitations for the afﬂicted, than in
high-income countries where aids such as motorized wheelchairs
and buildings that cater for wheelchair access are commonplace.
The perceived unavailability of utility weights using country-
speciﬁc preferences could be one of the barriers in LMICs to the
adoption of health economic evaluation as a formal tool for
decision making [1].
Aim
This article presents a systematic review of the literature with
the aim of ascertaining HSV studies that have been undertaken in
LMICs, and the valuation methods that have been used. This
review is important to further develop standardized methods for
HSV for use in CUAs. It suggests areas for improvement in the
application of the methods and how resource-poor conditions
can develop their own HSVs for use in CUAs to improve decision
making.Methods
A comprehensive search of the literature was carried out by using
Medline, PubMed, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), and American Economic Association’s Elec-
tronic bibliography (EconLit) databases. The search was restricted
to publications from 1976 to August 2012 for all languages. All
four databases were searched, using the same strategy, for the
words below appearing in the title, abstract, or full text of the
article:1. “Quality of life”
2. “util*” or “preference*” or “health state*” or “value set”
3. “time trade off” or “TTO” or “time-trade off “or “time trade-off”or “SG” or “standard gamble” or “conjoint analysis” or “DCE” or
“discrete choice experiment*”
The search terms were combined by using the Boolean term
“AND” (#1 AND #2 AND #3) to achieve the ﬁnal search result.
In addition, reference searches were carried out in Web sites
of the major HSV systems for the EQ-5D questionnaire [25],
Assessment of QOL (AQOL) [26], and SF-6D [27]. Last, references
in the selected articles from the original search and references of
recent reviews and valuation studies from high-income countries
were reviewed to identify any further studies from LMICs.
Articles were selected according to the following criteria.
Inclusion Criteria1. Generic or disease-speciﬁc HSV studies using a TTO, SG, or
DCE from an LMIC (if one LMIC was available in a multiple
country study, details for the LMIC were included).
Exclusion Criteria1. HSV studies from high-income countries. Hong Kong was
considered as a high-income zone despite being associated
with China, which is an LMIC according to the World Bank [21].2. Studies using nontrading methods such as the visual ana-
logue scale (VAS). Although the VAS is a valuation method, it
is not choice-based and provides rankings only. Thus, it was
excluded on the basis that valuations derived from a VAS are
not preferences involving explicit trade-offs. None of the VAS
studies found was from an LMIC.3. Nonempirical articles discussing methodological or theoret-
ical issues of preference-based measures, health state
descriptive systems, and review studies.4. Other: articles such as CUA studies that apply existing utility
weights.
The review followed the Preferred Reporting System for
Systematic Reviews and Meta-Analysis (PRISMA) strategy
(Fig. 1), which allows systematic selection of articles and is
described in detail elsewhere [28].
The selected articles were categorized into two groups, namely,
generic HSV studies and disease-speciﬁc HSV studies. The selected
generic HSV studies were compared with each other with respect to
the descriptive systems used, the number of health states directly
valued (total and per subject), the preference elicitation method
used, the model used for estimation, dependent and independent
variables used, and measurements of the model ﬁt. Disease-speciﬁc
HSVs were also compared with each other for their methodology,
results, and utilities of the speciﬁc disease conditions.Results
Sixteen articles were selected from the database search (Fig.1).
The EUROQoL Web site identiﬁed one additional relevant article
[29], making a total of 17 for inclusion in the review. It was
noteworthy that of the 943 selected articles, only 16 (1.7%) were
from LMICs (Fig. 1). Nine of the 17 selected studies were sourced
from the Asian continent [30–38], four from South America
[39–42], three from Africa [29,43,44], and one from Australasia
[45]. Twelve studies were undertaken in upper middle income
countries [30–33,35–37,39,40–42,44], three in lower middle income
countries [34,38,45], and two in low-income countries [29,43].
Table 1 shows that only 11.8% of the countries classiﬁed as LMIC
have any experience in valuing health states. Compared with
low- and lower middle income countries, a higher percentage of
upper middle income countries reported HSVs (Table 1).
* 1,2,3,4 relate to the four exclusion criteria 
Total selected papers 1395
Title read 943 
Full articles read 78 
Abstracts read 355 
Selected papers 16 
Duplicates – 452 – 4 
databases produced 
same article as result 
Excluded- 588 
 1. High income- 90 
2. Non trade-off- 3 
3. Nonempirical- 268 
4. Not relevant- 227 
Excluded- 277 
1. High income-232 
2. Non trade-off-5 
3. Nonempirical-33 
4. Not relevant -7 
Excluded- 62 
 1. High income-51 
2. Non trade-off-1 
3. Nonempirical-8 
4. Not relevant -2 
Total Selected papers 17 
Additional searches 1 
Fig. 1 – PRISMA ﬂowchart for the selection of articles for the review. *1, 2, 3, and 4 relate to the four exclusion criteria. PRISMA,
Preferred Reporting System for Systematic Reviews and Meta-Analysis.
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There were seven generic HSV studies [29,30,36,39,40,42,45],
including one undertaken in adolescents rather than adults [45].
Of the seven generic HSV studies, ﬁve were from upper middleTable 1 – Number of countries that reported health
state valuations in LMICs.
Income
group
Number of
countries
that reported
health state
valuations
Number of
countries in
the income
group
Percentage
Upper middle 12 54 22
Lower middle 3 54 5.5
Low 2 36 5.5
All LMICs 17 144 11.8
LMICs, low- and middle-income countries.income countries. The remaining 10 articles were disease-speciﬁc
HSV studies [31–35,37,38,41,43,44]. TTO was the predominant
valuation method. It was used 10 times, while the SG was used
7 times (on 5 of these occasions, the SG was used in addition
to the TTO). No study used DCEs. One study, however, used
willingness to pay as a method additional to TTO [35]. Valuations
were undertaken for generic instruments (the EQ-5D question-
naire, SF-6D, and AQOL), and disease-speciﬁc states of rheuma-
toid arthritis, HIV, melasma, colorectal cancer, and glaucoma
states.Generic HSV Studies
Five of the seven generic studies had valued EQ-5D questionnaire
health states [29,30,36,40,42] (Table 2). The other two studies
valued the SF-6D [39] and the AQOL [45]. Tongsiri and Cairns [30],
Yusof et al. [36], Zarate et al. [42], and Augustovski et al. [40] used
translated and validated EQ-5D questionnaire descriptive sys-
tems in local languages. However, Jelsma et al. [29] used only the
English version in Zimbabwe, and their study thus suffers from
Table 2 – Description of the selected health state valuation studies for the review.
Publication Country class Country Sample size Sample description Valuation method Instrument or disease valued Type of
study
Yusof et al. [36] Upper middle Malaysia 152 Health professionals TTO EQ-5D questionnaire GHSV
Leeyaphan et al. [35] Upper middle Thailand 77 Patients with melasma TTO/WTP Melasma DSHV
Dranitsaris et al. [37] Upper middle Malaysia 24 Health professionals TTO Colorectal cancer DSHV
Dranitsaris et al. [38] Lower middle India 24 Health professionals TTO Colorectal cancer DSHV
Zarate et al. [42] Upper middle Chile 2000 General public TTO EQ-5D questionnaire GHSV
Tongsiri and Cairns [30] Upper middle Thailand 1409 General public TTO EQ-5D questionnaire GHSV
Cruz et al. [39] Upper middle Brazil 494 General public SG SF-6D GHSV
Moodie et al. [45] Lower middle Fiji/Tonga 60 Adolescents TTO AQOL GHSV
Goncalves Campolina et al. [41] Upper middle Brazil 200 General public TTO/SG RA DSHV
Augustovski et al. [40] Upper middle Argentina 679 General public TTO EQ-5D questionnaire GHSV
Sakthong et al. [31] Upper middle Thailand 120 Patients with HIV TTO/SG HIV DSHV
Sun et al.[32] Upper middle China 106 Patients with glaucoma TTO/SG Glaucoma DSHV
Levy et al. [33] Upper middle China 100 Patients with hepatitis SG Hepatitis B DSHV
Lara et al. 2008 [43] Low Uganda 435 Patients with HIV TTO/SG HIV DSHV
Gupta et al. [34] Lower middle India 105 Patients with glaucoma TTO/SG Glaucoma DSHV
Bejia et al. [44] Upper middle Tunisia 122 Patients with RA TTO RA DSHV
Jelsma et al. [29] Low Zimbabwe 2488 General population TTO EQ-5D questionnaire GHSV
Notes: Country class according to World Bank classiﬁcation per capita income of the countries [21].
The AQOL study [40] reported results from both Fiji and Tonga and is considered here as one study.
AQOL, Assessment of Quality of Life; DSHV, disease-speciﬁc health state valuation; EQ-5D, EuroQol ﬁve-dimensional; GHSV, generic health state valuation; RA, rheumatoid arthritis; SF-6D, six-
dimensional health state short form (derived from short-form 36 health survey); SG, standard gamble; TTO, time trade-off; WHOQOL, World Health Organization Quality of Life assessment
instrument [44,45]; WTP, willingness to pay.
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Table 3 – Comparison of Generic health state valuation studies.
Yusof et al.
[36]
Zarate et al.
[42]
Tongsiri and
Cairns [30]
Augustovski
et al. [40]
Jelsma et al.
[29]
Cruz et al.
[39]
Moodie et al.
[45]
Country Malaysia Chile Thailand Argentina Zimbabwe Brazil Fiji/Tonga
Sample N ¼ 152
convenient
N ¼ 2000
multistage
probability
N ¼ 1409 random
representative
N ¼ 611 convenient N ¼ 2384 random N ¼ 494
random
N ¼ 60 convenient
Age description (y) Mean 41 Mean 46 Mean 44.6 ≥18, mean 43.5 ≥15 20–64 12–18
Mode of interview Face to face Face to face Face to face Face to face Face to face Face to face Class setting
Total directly valued
states
45 42 86 24 38 248 30 scenarios
No. of states directly
valued per person
15 12 10 13 7 6 10 scenarios
Use of worse-than-
death states
Yes? Yes No information Yes 33333 was the only state
valued as worse than dead
Yes Monash protocol
[40]
Reliability of data No data No data No data No data No data No data No data
Exclude logical
inconsistencies
Yes Yes No No data No No No data
Regression model Linear
additive
Additive RE Additive GLS RE Additive OLS plus
Huber White
method
Additive REML Additive RE Multiplicative
Analysis method Individual
level
Individual level No information Individual level No information Individual
and
aggregate
Individual and
aggregate
Dependent variable No
information
1-S 1-S No data TTOs* /10 SGs* 1-S
Independent
variables
“Main effect
model” N3,
D1
“Main effect” “Main effect
model,” N3,
intercept
16 variable model “Main effect model” – AQOL score
demographic
variables
Number of
independent
variables
10 for the
main effect
10 11 16 10 16 No data
R2 0.427 for D1 0.337 for N3 0.448 0.897 No data No data No data
MAD o 0.05 Yes Yes Yes Yes Yes No No data
Best utility for a
disease state
0.879 0.808 0.766 0.931 0.857 0.82 No data
GLS, generalized least square; MAD, mean absolute difference; OLS, ordinary least square; 1-S, disutility; RE, random effect; REML, residual maximum likelihood linear mixed model; R2, co-
efﬁcient of determination; SG, standard gamble; TTO, time trade-off.
 Value of a given health state TTO or SG.
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 9 1 – 1 0 9 91096selection bias. Cruz et al. [39] used the Brazilian language for the
SF-6D, while Moodie et al. [45] in their AQOL study used English.
The reported EQ-5D questionnaire and SF-6D studies generated
their respective country population tariffs for utility weights. The
AQOL study was a calibration study for adolescents [45]. The
methodological approach used by generic HSV studies is sum-
marized in Table 3. The studies used sample sizes ranging from
152 to 2384 in the six studies that collected data from the general
population [29,30,36,39,40,42]. The AQOL study included only
adolescents (aged 12–18 years with a sample size of 60) [45].
Moodie et al. [45] also undertook the valuation in a classroom
setting, which is quite different from the individual level of data
collection seen in other TTO valuations.
The number of directly valued health states ranged from 24 to
248. The EQ-5D questionnaire studies directly valued different
numbers of health states: 24 [40], 38 [29], 42 [42], 45 [36], and 86
[30]. The SF-6D study valued 248 health states, while the AQOL study
valued 30 scenarios. The EQ-5D questionnaire studies reported a
range of 7 to 15 valuations per person (Table 3). The SF-6D study
used 6 valuations per person, and the AQOL study used 10.
Jelsma et al. [29] reported TTO value/10 as the dependent
variable, a deviation from using disutility as the dependent
variable [29]. The only SF-6D study described in this review is
that by Cruz et al. [33]. They ﬁtted individual- and aggregate-level
models to SG valuations and estimated utility weights for all SF-
6D health states following the example of Brazier et al [11].
Moodie et al. [45] used TTO scores for the scenarios used as the
dependent variable. Except for Augustovski et al., who reported
−19 as the lower bound for worse than death states before
transformation to interval scale, indicating 6-month TTO incre-
ments, others did not report worse than death values before
transformation. Yusof et al. [36] and Zarate et al. [42] reported
exclusion of logical inconsistencies, while Tongsiri and Cairns
[30], Jelsma et al. [29], and Cruz et al. [39] did not exclude them.
All generic HSV studies used regression models with additive
functional forms, except for Moodie et al. [45] who used a multi-
plicative functional form in the model estimation. Tongsiri and
Cairns [30] were the only authors to use a generalized least square
random effect model [15]. Others [29,40] used variations of linear
regression for EQ-5D questionnaire studies. Using the Huber-White
method in their model estimation, Augustovski et al. [40] allowed
for heteroscedasticity correction for the uneven variance across
observations. These studies speciﬁed between 10 and 16 independ-
ent variables according to the model used. Moodie et al. [45] used
demographic variables and AQOL scores for independent variables.
In contrast to individual-level analysis in EQ-5D questionnaire
studies, Cruz et al. [39] used an aggregate-level analysis. There
was general consensus in using the main effects model for the
independent variables in the EQ-5D questionnaire studies. It was
unclear, however, that the use of a different number of independent
variables improved the model ﬁt. Augustovski et al. [40] used a
different model, called the “16 variable” model, which incorporated
both N3 [15] and D1 models [13]. Cruz et al. [39] used a random
effect model to derive their estimates.
The predictive power of a regression model can be seen by
how well the model predicts values from an internal sample
against an external sample. If the mean absolute difference, a
measure of statistical dispersion, is less than 0.05, the model is
considered to be robust with good predictive power. All ﬁve EQ-
5D questionnaire studies [29,30,36,40,42] reviewed here met this
criterion. In comparing the best utility for a disease state, the
values ranged from 0.766 to 0.931 (Table 3).
Disease-Speciﬁc HSV Studies
No study from the selected publications valued health states
from an existing validated disease-speciﬁc MAUI. Of the 10disease-speciﬁc HSV studies found in the literature, two valued
health states in HIV-positive individuals [43,46], two valued
health states in glaucoma [32,34], and two in rheumatoid arthritis
[41,44]. One study valued chronic hepatitis B [33], one melasma
[35], and two studies valued colorectal cancer health states
[37,38]. All disease-speciﬁc HSV studies were from Asian and
African countries and are compared further in their methodology
in Table 4.
All seven studies used convenience sampling. The sample size
ranged from 24 to 435. The respondents were all patients and
health professionals except in the study of Levy et al. [33] who
recruited people both with and without hepatitis B infection. The
majority of these studies recruited consecutive patients attend-
ing clinics, except for that of Lara et al. [43] who recruited from an
ongoing trial of HIV-positive patients. In contrast, Dranitsaris
et al. opted to have nurses as surrogates to value colorectal
cancer health states in two similar studies undertaken in Malay-
sia [37] and India [38].
Except for two studies [33,43], most other disease-speciﬁc HSV
studies [32,34,35,41,44,46] used respondent patients’ own health
state to trade-off against full health. Lara et al. [43] used three HIV
health states constructed from World Health Organization HIV
stages, and calibrated these with both clinicians and patients.
There was no perfect health state for comparison but an
improved health state that was given the utility value of 1. Levy
et al. [33] developed six hepatitis B health states with the help of
experts and used extensive consensual validation, forward and
backward translations, linguistic validation interviews, and pilot
testing.Discussion
Overall, this systematic review shows the paucity of HSV evi-
dence available from LMICs. Moreover, only six studies reported
HSVs for population norms. Only a handful of upper middle
income countries have developed their own utility weights and
still fewer lower middle income and low-income countries have
done so. LMICs make up the larger proportion of the world’s
population and have the greatest disease burden [22,47–49].
Utility weights are instrumental in efﬁcient resource allocation
in health care. In valuing health states for the EQ-5D question-
naire and the SF-6D, the reported studies generally followed the
protocol put forwarded by earlier studies [10,50] but with some
variations. The variations included the choice of directly valued
health states, use of health states worse than death, and the
regression model selected for the model estimation. No article
discussed or justiﬁed the different independent variables used in
the regression models or the interactions between dimensions in
their models.
None of the studies gave a rationale for the number or the
selection of the directly valued health states. There was no
reason given for the different selection of directly valued health
states. Nevertheless, it is deemed acceptable to use any number
of health states for direct valuation as long as these legitimately
represent the EQ-5D questionnaire valuation space and do not
include implausible states [17]. It would, however, be better to
directly value as many health states as possible without over-
burdening the respondents, keeping the duration of the valuation
exercise to less than 30 minutes [17]. The majority of the studies
reported in this review have valued 10 to 15 health states per
respondent. It is possible, however, to directly value a larger
number of health states in a particular study without increasing
the number per respondent [17], while maintaining robust
estimates.
In general, the EQ-5D questionnaire studies in this review
report their sampling procedure poorly. Usually no or insufﬁcient
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convenience sampling. No study reported the power of their
sample sizes. A nonrepresentative sample would not produce a
reliable decision-making tool. Even if the sample was not ran-
dom, if it does not vary signiﬁcantly from the demographic proﬁle
of the population it could be argued that the derived values could
reasonably be held to represent population-based preferences.
Jelsma et al. [29] and Augustovski et al. [40] produce comparisons
of their respective samples with the demographic data of their
countries in an attempt to validate this approach. Signiﬁcant
interviewer effects were also reported by Jelsma et al. [29]. Thus,
it is important to use educated, trained, and calibrated inter-
viewers who can grasp the TTO process and are also capable of
training the subjects, especially in LMIC community survey
scenarios.
The utility values produced from disease-speciﬁc HSV studies
in this review cannot be compared with each other because they
did not use the same methods. All studies other than Levy et al.
[33] valued preferences between a patient’s own current health
state and undertaking a risky intervention to gain perfect health.
The Indian study on glaucoma [34] used immediate death for SG,
in contrast to the Chinese study that used blindness as the
gamble [32]. It is doubtful that these utilities could be used for
any decision-making exercise, but nevertheless serve a descrip-
tive purpose and do allow comparison with other interventions
for the same disease. Most of these studies used the presumed
life expectancy of the subject as the time horizon. Thus, the
denominator in the TTO or SG equation was each person’s life
expectancy from the age the person was when valuing the health
state. Furthermore, in the majority of cases, the trade-offs were
made against their own disease state versus perfect health. The
preferred method of utility valuation for disease-speciﬁc health
states is to build disease scenarios with the help of patients and
value them in standard conditions by healthy subjects who
represent the population [2]. Given the challenge to conduct
health state valuations in LMICs, especially in Africa and South
Asia, the above disease-speciﬁc HSV studies are commendable.
A clear limitation is the lack of local research capacity in
many of these countries. Health economic evaluations are very
rare in LMICs [21] than in high-income countries. One reason for
the dearth of publications from these countries is the limited
number of researchers in health economics. Then, there is the
question of cost. Unlike the situation in high-income countries,
the costs of data collection, including salaries of data collectors
and for logistics, are much lower in LMICs. Collaboration with
health economists from high-income countries and capacity
building of personnel in LMICs can promote the development of
country-speciﬁc utility weights from LMICs. Subsequently,
greater awareness among health decision makers of the value
and relevance of utility weights should lead to improved alloca-
tion of health resources.
The social and economic aspects of health care may be
disregarded in many countries because of the lack of under-
standing among health professionals and decision makers about
these aspects [1]. Changing social expectations may also demand
that health beneﬁt packages should include lifesaving inter-
ventions irrespective of their cost-effectiveness. An inherent
problem of these countries where health resource allocation
(and all resource allocations) is more politicized, decision makers
could feel their authority challenged if the results of economic
evaluations were to be followed [51]. As an example, in Japan,
clinicians felt their clinical autonomy challenged when health
economic evaluations were proposed [1]. Social institutions
would demand that decision makers consider not only the
efﬁciency but also the norms and values in the society, equity,
social solidarity, and protection against catastrophic health
expenditure. The prevailing health systems in these countries
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 9 1 – 1 0 9 91098still revere health professionals, have strong traditions, and are
reluctant to discuss economic aspects on the basis of altruism [1].
The comparison of health services with monetary values could
still be unacceptable to them. The principles of utilitarianism on
which health economic evaluations are based might not be
considered ethical, especially in an Asian mindset where “max-
imum happiness” or “maximum pleasure” would not align with
the “middle way” of Buddhism or Hinduism in a philosophical
sense [1]. However, Cubbon [52] has counterargued this by saying
that it is absurd to think that QALYs matter only to people living
in Western liberal democracies, advanced capitalist societies, or
welfare states. As the author reasoned, pain and disability have
always been the limiting factor in preventing humans achieving
their goals. Thus, achievement of the goals of every member of
society needs to be promoted. Thus, QALYs become very impor-
tant where evaluation of life without regard to actual or potential
quality would be incomplete [52].
LMICs are challenged by large population growth and huge
disease burdens coupled with inefﬁcient, unwieldy health sys-
tems [22]. People in these countries could beneﬁt immensely if
CUAs were to be used to facilitate health care decision making.
CUAs, however, need relevant HSVs because weights from other
countries such as those from Western Europe, which are so
socioeconomically and culturally different, cannot be applied [23].
The QALY is one of two methods that allow quantiﬁcation of
QOL and survival and is used as a building block of health policy
[52]. The other is the DALY [6,7]. CUA is required to make
objective health care decisions. It is very much necessary to
promote research and application of these approaches in LMICs.
One of the foremost actions should be valuation of utility weights
for speciﬁc countries using reliable and valid MAUI to facilitate
future research in this ﬁeld.Conclusions
This literature review demonstrates that utility weight valuations
from LMICs are rare, compared with high-income developed
countries. LMICs have the majority of the world’s population
and the highest disease burden [22]. There is a need to conduct
HSV studies to produce utility scoring algorithms for these
countries. It is recommended that the quality of utility weight
valuation studies be improved by deriving and validating MAUIs
in LMICs. For disease-speciﬁc HSV studies, when scenarios are
constructed they should be validated prior to use. Moreover,
health economic research should focus on validating disease-
speciﬁc MAUIs, at least for the diseases with the largest public
health burden. Greater collaborative research between health
economics centers in high-income countries and LMICs could
pave the way to capacity building in LMICs. International agen-
cies should be encouraged to increase funding in this regard.
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